ADReCS

Pharmaceutical Information

Drug Name	Acetylcysteine
Drug ID	BADD_D00032
Description	Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of [acetaminophen] overdose.[L31378,L31383,L31388,L31478] Acetylcysteine has also been studied for a wide variety of off-label indications with mixed results.[A228158,A228163,A228168] Acetylcysteine was granted FDA approval on 14 September 1963.[L31488]
Indications and Usage	Acetylcysteine is indicated for mucolytic therapy and in the management of [acetaminophen] overdose.[L31378,L31383,L31388,L31478]
Marketing Status	approved; investigational
ATC Code	R05CB01; S01XA08; V03AB23
DrugBank ID	DB06151
KEGG ID	D00221
MeSH ID	D000111
PubChem ID	12035
TTD Drug ID	D06XGW
NDC Product Code	70594-111; 12598-7311; 49452-0098; 51552-0201; 51927-1601; 63323-694; 70710-1015; 55150-259; 66220-207; 0517-7610; 55154-5731; 12598-7302; 12598-7308; 12598-7323; 14445-412; 63323-963; 0409-3307; 0517-7504; 0517-7630; 72611-860; 83270-001; 25021-812; 63323-693; 63323-695; 0409-3308; 0517-7604; 17478-660; 63323-690; 63323-692; 0517-7510; 70771-1412; 52932-0704; 63323-691; 12598-7027; 52951-001; 0574-0805; 12598-7294; 12598-7327; 52133-0002; 52932-0742; 55154-5730
UNII	WYQ7N0BPYC
Synonyms	Acetylcysteine \| N-Acetyl-L-cysteine \| N Acetyl L cysteine \| N-Acetylcysteine \| N Acetylcysteine \| Mercapturic Acid \| Acid, Mercapturic \| Solmucol \| Genac \| Acemuc \| Acetabs \| Acetylcystein AL \| NAC AL \| Acetylcystein Atid \| Acetylcystein Heumann \| Acetylcystein Trom \| Acetylcysteine Hydrochloride \| Hydrochloride, Acetylcysteine \| Acetylcysteine Sodium \| Sodium, Acetylcysteine \| Acetylcysteine, Monosodium Salt \| Monosodium Salt Acetylcysteine \| Acetylcysteine Zinc \| Zinc, Acetylcysteine \| Acetylcysteine, (D)-Isomer \| Acetylcysteine, (DL)-Isomer \| Acetylcysteine, Monoammonium Salt \| Monoammonium Salt Acetylcysteine \| Acetyst \| Acétylcystéine GNR \| Airbron \| Alveolex \| Bromuc \| Azubronchin \| Bisolvon NAC \| NAC, Bisolvon \| Broncho-Fips \| Broncho Fips \| BronchoFips \| Broncholysin \| Broncoclar \| Codotussyl \| Cystamucil \| Dampo Mucopect \| Mucopect, Dampo \| durabronchal \| Larylin NAC \| Eurespiran \| Exomuc \| Fluimucil \| NAC Zambon \| Zambon, NAC \| Fabrol \| Fluprowit \| Optipect Hustengetränk \| Hustengetränk, Optipect \| Muco Sanigen \| Sanigen, Muco \| Frekatuss \| Jenacystein \| Jenapharm \| Lantamed \| Lindocetyl \| M-Pectil \| M Pectil \| MPectil \| mentopin Acetylcystein \| Acetylcystein, mentopin \| Muciteran \| Mucomyst \| Acetylin \| Mucosil \| Mucosol \| Mucosolvin \| Siccoral \| Siran \| Ilube \| Hoestil \| acebraus

Chemical Information

Molecular Formula	C5H9NO3S
CAS Registry Number	616-91-1
SMILES	CC(=O)NC(CS)C(=O)O
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Drug abuse	19.07.06.010	0.000149%		Not Available
Drug hypersensitivity	10.01.01.001	0.001086%		Not Available
Drug ineffective	08.06.01.006	0.001518%		Not Available
Drug interaction	08.06.03.001	0.000149%		Not Available
Dyspepsia	07.01.02.001	0.000327%
Dysphagia	07.01.06.003	0.000149%
Dysphoria	19.04.02.004	-	-	Not Available
Dyspnoea	02.11.05.003; 22.02.01.004	0.001369%
Ear disorder	04.03.01.001	-	-	Not Available
Ear pain	04.03.01.003	0.000446%
Encephalopathy	17.13.02.001	0.000298%
Erythema	23.03.06.001	0.001175%		Not Available
Extravasation	08.01.03.008	0.000402%		Not Available
Eye pain	06.08.03.002	-	-
Face oedema	23.04.01.004; 10.01.05.002; 08.01.07.003	-	-
Feeling hot	08.01.09.009	-	-	Not Available
Flushing	24.03.01.002; 23.06.05.003; 08.01.03.025	0.000149%
Gait disturbance	15.03.05.013; 17.02.05.016; 08.01.02.002	-	-
Gastrointestinal disorder	07.11.01.001	-	-	Not Available
Generalised oedema	14.05.06.007; 08.01.07.004	0.000223%
Generalised tonic-clonic seizure	17.12.01.002	0.000223%		Not Available
Haemolysis	01.06.04.002	0.000149%
Haemolytic anaemia	01.06.03.002	0.000223%		Not Available
Haemolytic uraemic syndrome	01.06.02.001; 20.01.03.011	0.000149%
Haemoptysis	02.11.04.009; 24.07.01.006; 22.02.03.004	-	-	Not Available
Hepatic cirrhosis	09.01.04.001	0.000223%		Not Available
Hepatic encephalopathy	17.13.01.003; 09.01.03.006	0.000298%		Not Available
Hepatitis	09.01.07.004	0.000298%		Not Available
Hepatotoxicity	12.03.01.008; 09.01.07.009	0.000521%		Not Available
Hyperbilirubinaemia	09.01.01.003; 01.06.04.003; 14.11.01.010	0.000149%		Not Available

The 2th Page First Pre 2 3 4 5 Next Last Total 5 Pages